R&D

Lilly gains panel's backing to expand Cymbalta use

August 19, 2010
Bloomberg News
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis of studies in lower back pain and osteoarthritis of the knee.
More

Lilly Alzheimer's drug prospect only the latest to fail

August 18, 2010
Bloomberg News
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the disease since 1906, have failed in mid- to late-stage testing since 2003.
More

Lilly's Cymbalta helps chronic pain in U.S. review

August 17, 2010
Bloomberg News
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's annual sales.
More

Lilly braces for plunge in profits

August 14, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of loss of revenue that it's hard to picture what the company will look like in five years.
More

Contract pharmaceutical research firm expands to New JerseyRestricted Content

July 10, 2010
J.K. Wall
Concentrics grows in spite of recession as drug companies look for help to handle patent expirations
More

Lilly's Lechleiter: No change in plans

July 7, 2010
J.K. Wall
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no mega-merger.
More

Marcadia enlists Lilly to help develop new diabetes drug

June 28, 2010
J.K. Wall
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s current Glucagon for patients with severe hypoglycemia.
More

Q&A

June 23, 2010
J.K. Wall
David Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science. He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its quest.
More

Research reforms will force Lilly, others to test how drugs stack upRestricted Content

June 12, 2010
J.K. Wall
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness research could threaten their sales.
More

Closing of Purdue's Chao Center is setback for BioCrossroads

May 1, 2010
J.K. Wall
The university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured small batches of drugs used in clinical trials.
More

Harlan Labs names new CEO

April 23, 2010
 IBJ Staff
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
More

Lilly sues to block generic of Adcirca lung treatment

March 17, 2010
Bloomberg News
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
More

Lilly pays $50M-plus for rights to testosterone lotion

March 16, 2010
Bloomberg News
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing assets are transferred, but the deal could be worth millions more.
More

Lilly, Merck, Pfizer starting research center

February 23, 2010
Associated Press
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
More

Teva gets European OK to sell generic of Lilly's Evista

February 19, 2010
Bloomberg News
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
More

Pfizer's Viagra patent partially rejected in Lilly fight

February 16, 2010
Bloomberg News
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn't different enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against Eli Lilly and Co. over its rival Cialis drug.
More

City of Greenwood might fund launch of insulin makerRestricted Content

January 30, 2010
Kathleen McLaughlin
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin, a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
More

Lilly looks to autoimmune drugs

January 27, 2010
J.K. Wall
Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat automimmune diseases: The costs of treating them are growing twice as fast as the prescription drug market.
More

Lilly launching new venture capital fund

December 10, 2009
J.K. Wall
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly's drug pipeline.
More

Lilly extends research pact with India firm

December 1, 2009
 IBJ Staff
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five years.
More

Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters

November 14, 2009
 IBJ Staff
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided locating here would give Aarden a better chance of success.
More

Lilly needs to sell more Effient before Zyprexa loses patent protectionRestricted Content

October 24, 2009
J.K. Wall
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for the quarter.
More

Eli Lilly CEO banking on new drug pipeline

October 22, 2009
Associated Press
CEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year career at the company. He's betting there will be a fourth.
More

Lilly, GE announce cancer diagnostic breakthrough

October 21, 2009
J.K. Wall
Eli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
More

Lilly's win in Evista patent case crucial, analyst says

September 24, 2009
Scott Olson
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.
More
Page  << 1 2 3 4 5 6 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am so impressed that the smoking ban FAILED in Kokomo! I might just move to your Awesome city!

  2. way to much breweries being built in indianapolis. its going to be saturated market, if not already. when is enough, enough??

  3. This house is a reminder of Hamilton County history. Its position near the interstate is significant to remember what Hamilton County was before the SUPERBROKERs, Navients, commercial parks, sprawling vinyl villages, and acres of concrete retail showed up. What's truly Wasteful is not reusing a structure that could still be useful. History isn't confined to parks and books.

  4. To compare Connor Prairie or the Zoo to a random old house is a big ridiculous. If it were any where near the level of significance there wouldn't be a major funding gap. Put a big billboard on I-69 funded by the tourism board for people to come visit this old house, and I doubt there would be any takers, since other than age there is no significance whatsoever. Clearly the tax payers of Fishers don't have a significant interest in this project, so PLEASE DON'T USE OUR VALUABLE MONEY. Government money is finite and needs to be utilized for the most efficient and productive purposes. This is far from that.

  5. I only tried it 2x and didn't think much of it both times. With the new apts plus a couple other of new developments on Guilford, I am surprised it didn't get more business. Plus you have a couple of subdivisions across the street from it. I hope Upland can keep it going. Good beer and food plus a neat environment and outdoor seating.

ADVERTISEMENT